PE20191238A1 - Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado - Google Patents
Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutadoInfo
- Publication number
- PE20191238A1 PE20191238A1 PE2019000923A PE2019000923A PE20191238A1 PE 20191238 A1 PE20191238 A1 PE 20191238A1 PE 2019000923 A PE2019000923 A PE 2019000923A PE 2019000923 A PE2019000923 A PE 2019000923A PE 20191238 A1 PE20191238 A1 PE 20191238A1
- Authority
- PE
- Peru
- Prior art keywords
- crenolanib
- proliferative disorders
- treat
- mutations associated
- mutated flt3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416475P | 2016-11-02 | 2016-11-02 | |
| US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191238A1 true PE20191238A1 (es) | 2019-09-11 |
Family
ID=62020370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000923A PE20191238A1 (es) | 2016-11-02 | 2017-10-31 | Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11078541B2 (enExample) |
| EP (1) | EP3359155A4 (enExample) |
| JP (3) | JP2019532011A (enExample) |
| KR (2) | KR20200079351A (enExample) |
| CN (1) | CN108778276A (enExample) |
| AU (1) | AU2017353925A1 (enExample) |
| BR (1) | BR112019008762A2 (enExample) |
| CA (1) | CA3024012A1 (enExample) |
| CL (1) | CL2019001208A1 (enExample) |
| CO (1) | CO2019005466A2 (enExample) |
| EA (1) | EA201991078A1 (enExample) |
| HK (1) | HK1257195A1 (enExample) |
| IL (1) | IL266303A (enExample) |
| MX (1) | MX2019005008A (enExample) |
| PE (1) | PE20191238A1 (enExample) |
| PH (1) | PH12019500965A1 (enExample) |
| SG (1) | SG11201903889TA (enExample) |
| WO (1) | WO2018085292A1 (enExample) |
| ZA (1) | ZA201903089B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1257195A1 (zh) * | 2016-11-02 | 2019-10-18 | 安罗格制药有限责任公司 | 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| CN109678849A (zh) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | 一种抗癌药物的制备方法 |
| US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN110531016B (zh) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | 一种hyml-122血药浓度定量分析方法 |
| CA3186319A1 (en) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN112921091B (zh) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| JP2023063189A (ja) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| IL162203A0 (en) | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| RU2005106871A (ru) | 2002-08-14 | 2005-10-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы протеинкиназ и их применение |
| BR0313743A (pt) | 2002-08-23 | 2005-07-05 | Chiron Corp | Benzimidazol quinolinonas e usos destas |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| SG148864A1 (en) | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| CN100404530C (zh) | 2003-06-24 | 2008-07-23 | 辉瑞产品公司 | 1-[2-(苯并咪唑-1-基)喹啉-8-基]哌啶-4-基胺衍生物的制备方法 |
| EP3354753B1 (en) * | 2009-04-06 | 2020-02-12 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
| AU2013232379A1 (en) * | 2012-03-12 | 2014-09-25 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
| KR20140040594A (ko) | 2012-09-26 | 2014-04-03 | 아로그 파마슈티칼스, 엘엘씨 | 돌연변이체 c-kit의 억제 방법 |
| BR112015016282A2 (pt) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| HK1257195A1 (zh) * | 2016-11-02 | 2019-10-18 | 安罗格制药有限责任公司 | 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
-
2017
- 2017-10-31 HK HK18116172.6A patent/HK1257195A1/zh unknown
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/es unknown
- 2017-10-31 EA EA201991078A patent/EA201991078A1/ru unknown
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/ko not_active Ceased
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/ko not_active Ceased
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en not_active Ceased
- 2017-10-31 BR BR112019008762A patent/BR112019008762A2/pt not_active Application Discontinuation
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/es unknown
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/zh active Pending
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/ja active Pending
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/es unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/es unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US12404555B2/en active Active
-
2022
- 2022-03-02 JP JP2022031616A patent/JP7536320B2/ja active Active
-
2024
- 2024-04-11 JP JP2024064106A patent/JP2024096859A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,777 patent/US20250305063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500965A1 (en) | 2019-12-02 |
| CL2019001208A1 (es) | 2019-07-26 |
| AU2017353925A1 (en) | 2018-09-27 |
| US20210324481A1 (en) | 2021-10-21 |
| KR20200079351A (ko) | 2020-07-02 |
| JP2022071099A (ja) | 2022-05-13 |
| IL266303A (en) | 2019-06-30 |
| MX2019005008A (es) | 2019-09-10 |
| JP7536320B2 (ja) | 2024-08-20 |
| US11078541B2 (en) | 2021-08-03 |
| KR20180074792A (ko) | 2018-07-03 |
| ZA201903089B (en) | 2019-12-18 |
| EP3359155A1 (en) | 2018-08-15 |
| CO2019005466A2 (es) | 2019-07-31 |
| EP3359155A4 (en) | 2019-05-22 |
| WO2018085292A1 (en) | 2018-05-11 |
| CN108778276A (zh) | 2018-11-09 |
| EA201991078A1 (ru) | 2019-11-29 |
| US12404555B2 (en) | 2025-09-02 |
| US20180117031A1 (en) | 2018-05-03 |
| SG11201903889TA (en) | 2019-05-30 |
| HK1257195A1 (zh) | 2019-10-18 |
| BR112019008762A2 (pt) | 2019-07-16 |
| CA3024012A1 (en) | 2018-05-11 |
| JP2019532011A (ja) | 2019-11-07 |
| US20250305063A1 (en) | 2025-10-02 |
| JP2024096859A (ja) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191238A1 (es) | Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| CO2018000113A2 (es) | Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina | |
| MX389958B (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| PE20170523A1 (es) | Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| TN2019000033A1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| EP3400011A4 (en) | ANTI-CD20 COMBINATIONS FOR THE TREATMENT OF TUMORS | |
| SG11201608218QA (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| EP3419639A4 (en) | AAV IDUA VECTOR FOR TREATING BLINDNESS IN CONNECTION WITH MPS I | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| PL3432872T3 (pl) | Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego | |
| UY35359A (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO | |
| LT3687567T (lt) | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| HUE052187T2 (hu) | Helyettesített pirido[3,4-b]indolok porcrendellenességek kezelésére | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| AU2015295120A8 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| IT201600130012A1 (it) | Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale | |
| SI3413870T1 (sl) | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni | |
| CR20150659A (es) | Derivados de prodroga de triazolpiridinas sustituidas |